Other languages Knight Therapeutics Inc.

Equities

GUD

CA4990531069

Market Closed - Toronto S.E. Other stock markets 16:00:00 2024-05-31 EDT			5-day change	1st Jan Change
6 ^CAD	+3.63%		-.--%	+15.61%

05-09	Knight Therapeutics Up Near 3% After Announcing Supply and Distribution Agreement For ADHD Medication; Despite Mixed Q1	MT
05-09	Transcript : Knight Therapeutics Inc., Q1 2024 Earnings Call, May 09, 2024

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Knight Therapeutics Up Near 3% After Announcing Supply and Distribution Agreement For ADHD Medication; Despite Mixed Q1	05-09
Transcript : Knight Therapeutics Inc., Q1 2024 Earnings Call, May 09, 2024	05-09
Knight Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09
Knight Therapeutics Brief: Q1 Net loss was $4.546 Million; Revenues were $86.604 Million	05-09
Knight Therapeutics Brief: Entering into Exclusive Supply and Distribution Agreement with Ironshore Pharmaceuticals & Development, Inc. for JORNAY PM In Canada and Latin America	05-09
Knight Therapeutics Reports First Quarter 2024 Results	05-09
Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Ironshore Pharmaceuticals & Development, Inc. for JORNAY PM® for Canada and Latin America	05-09
Knight Therapeutics Inc. Reconfirms Earnings Guidance for the Year 2024	05-09
Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Ironshore Pharmaceuticals & Development, Inc. for Jornay Pm® for Canada and Latin America	05-09
Knight Therapeutics Inc. announces voting results from the Annual General Meeting	05-08
Knight Therapeutics Inc. announces voting results from the Annual General Meeting	05-08
Knight to Present at the 2024 RBC Capital Markets Global Healthcare Conference in New York City	05-07
Notice of Knight Therapeutics' First Quarter 2024 Results Conference Call	05-02
Knight to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference	04-09
Knight Therapeutics Inc. ranks on The Globe and Mail’s fifth-annual Women Lead Here benchmark of executive gender diversity	03-28
Knight Therapeutics Price Target Raised to $7 at RBC	03-22
Knight Therapeutics Reports Fourth Quarter Results	03-21
Knight Therapeutics Inc. Provides Revenue Guidance for the Fiscal Year 2024	03-21
Transcript : Knight Therapeutics Inc., Q4 2023 Earnings Call, Mar 21, 2024	03-21
Knight Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-21

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Knight Therapeutics Inc.

Equities

GUD

CA4990531069

Other languages

Filters